Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY3723113 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Aficamten (BAY3723113) | EXPERIMENTAL | Aficamten will be administered orally once daily with or without food. Participants in this arm will receive a single daily oral dose of 5 mg, 10 mg, 15 mg, or 20 mg of Aficamten with dose levels guided by echocardiography assessments, for up to 24 weeks. Participants will receive a dose of Aficamten until the drug becomes commercially available in Japan or the study ends. |
| Name | Type | Description |
|---|---|---|
| BAY3723113 | DRUG | Oral tablet |
Inclusion Criteria: * Participant must be 18 to 85 years of age inclusive, at the time of signing the informed consent. * Diagnosed with HCM per the following criteria: 1. Has LV hypertrophy and non-dilated LV chamber in the absence of other cardiac disease and 2. Has an end-diastolic LV wall ...
BAY3723113 is an investigational small molecule being developed for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, a condition in which the heart muscle becomes thickened and obstructs blood flow. It is currently in Phase 3 clinical development.
BAY3723113 is being developed by Bayer AG, a multinational pharmaceutical company headquartered in Germany. Bayer's stock is traded on the OTC market under the ticker BAYRY.
BAY3723113 is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 3 study is currently active but not recruiting participants.
BAY3723113 is being studied in a Phase 3 clinical trial with the identifier NCT07023341. The trial is titled 'A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy' and is enrolling 36 participants in Japan.
Yes, BAY3723113 is also known as aficamten. The Phase 3 clinical trial NCT07023341 refers to the drug as aficamten, indicating that BAY3723113 and aficamten are the same compound.